Antidepressants : Types, Efficiency and Possible Side Effects.

Intro -- ANTIDEPRESSANTS: TYPES, EFFICIENCY AND POSSIBLE SIDE EFFECTS -- ANTIDEPRESSANTS: TYPES, EFFICIENCY AND POSSIBLE SIDE EFFECTS -- LIBRARY OF CONGRESS CATALOGING-IN-PUBLICATION DATA -- CONTENTS -- PREFACE -- Chapter 1 NEUROPLASTICITY: A NEW APPROACH TO TREATMENT OF DEPRESSION -- Abstract -- General Concepts and Information about Central Nervous System -- Neuron and its Structure -- Concept of Synapse and Neurochemical Transmission -- Neurotransmitters and Gene Regulation -- Principal Neuroanatomical Regions in the Central Nervous System with Functional Importance -- Mental Diseases, the Contribution of Stress and Hippocampal Disorders -- Hippocampus: Neuroanatomy, Histology and Hippocampal Neural Pathways -- Hippocampal Functions -- Depression and Neurobiology of Depression -- Noradrenergic System -- Serotonergic System -- Mood -- Hallucinations and Behavioral Changes -- Modulation of Sleep and Arousal -- Nociception -- Modulation of Eating and Drinking Behavior -- Other -- Monoamine Hypothesis of Depression -- Is The Monoamine Hypothesis Alone Sufficient to Explain Depression? -- Neuroplasticity Hypothesis -- Neuroplasticity -- What is Neuroplasticity? -- Association between Stress and Depression -- Synaptic Plasticity, Stress and the Effects of Antidepressant -- Breakage of Dendrites Due to Stress and the Effects of Antidepressants -- Stress, Hippocampal Volume and the Effects of Antidepressants -- Stress, Brain Metabolites and the Effects of Antidepressants -- Stress, Hippocampal Neurogenesis and the Effects of Antidepressants -- Stress, Hippocampal Apoptosis and the Effects of Antidepressant -- Stress, Postsynaptic Potential Changes and the Effects of Antidepressant -- Contribution of Glutamate in Stress Induced Neuroplasticity and the Effects of Antidepressants on Glutamatergic System.

Stress, Neurotrophic Factors and the Effects of Antidepressants -- Stress, Hippocampal Gene Expression and the Effects of Antidepressants -- Conclusion -- Acknowledgment -- References -- Chapter 2 ANTIDEPRESSANT THERAPY AND THE RISK OF SUICIDE AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDERS -- Abstract -- Introduction -- Antidepressants -- Data from Ecological Studies -- Data from Cohort and Case-Control Studies -- Randomized Controlled Trials (RCTs) -- Antidepressants and the Reduction of Suicide in Repeaters -- Implications of the Increasing Prescribing of SSRIs on Suicide in Different Countries -- Adverse Effect of Antidepressants and Suicide Mortality -- Conclusion -- References -- Chapter 3 MONITORING OF ANTIDEPRESSANT THERAPY BY USING HEART RATE VARIABILITY -- Abstract -- 1. Introduction - New Opportunities for Estimation of Cardiovascular Side Effects in Antidepressant Therapy -- 2. Side Effects of Antidepressant Drugs - Severe Impairment in Overdose -- 3. Depression, Antidepressant Therapy and Autonomic Nervous System - Association with Cardiac Disorders -- 4. Autonomic Nervous System, Heart Rate Variability (HRV) and Prognosis - Principles of HRV -- 5. Depression, Antidepressant Therapy and Heart Rate Variability - Synopsis of the Literature -- 6. Intoxication with Antidepressant Drugs - Mechanisms of Cardiac Impairment -- 7. Changes of Heart Rate Variability in TCA Intoxication - Detailed Information on Doxepin -- 8. Risk Of Higher Incidence of Arrhythmic Events in Doxepin Overdose - Differentiation of HRV Minimum and LF/HF Increase -- 9. Arrhythmic Events and Sympathovagal Balance - Correlation of Arrhythmic Incidence and LF/HF Increase -- 10. HRV Analysis in Time Course and Phase Dependent Side Effects - Changes of Blood Pressure and Heart Rate in Relation To HRV.

11. Methodical Limitations of HRV - Partially Contrary Results Caused by the Lack of Consensus -- 12. HRV Analysis in Antidepressant Therapy - Importance and Perspectives -- 13. Conclusion - HRV for Non-Invasive Improvement of Antidepressant Monitoring -- References -- Chapter 4 THE OVERLAP BETWEEN DEPRESSION AND SUICIDAL BEHAVIOUR: IMPLICATION FOR THE PREVENTATIVE EFFECT OF ANTIDEPRESSANT PHARMACOTHERAPY -- Abstract -- Introduction -- Relationship between Depression and Suicide -- Depression Among Suicides -- Suicide Risk in Depression -- The Suicidal Process in Depression -- Suicidal Process -- Suicidal Syndrome -- Treatment of Depression -- Efficacy of Antidepressant Pharmacotherapy -- Maintenance Treatment and Continuation Treatment -- Risk of Suicide During Treatment -- Co-Morbid Substance Use Disorders and Major Depression -- The Impact of Major Depression with Psychotic and Melancholic Features -- The Impact of Antidepressants on Suicidal Behaviour -- Undertreatment of Depression -- Randomised Studies -- Controlled Studies -- Ecological Studies -- Induction of Suicidal Behaviour? -- A Summary of the Problem -- References -- Chapter 5 SYNTHETIC INHIBITORS OF PROLYL ENDOPEPTIDASE EXHIBIT ANTIDEPRESSANT-LIKE EFFECTS IN RAT MODELS OF DEPRESSIVE SYNDROME AND ANXIETY-DEPRESSION STATE -- Abstract -- Introduction -- Methods -- Results -- Model I. Experimental MPTP-Induced Depressive Syndrome -- Discussion -- Conclusion -- References -- Chapter 6 BEYOND THE MONOAMINE HYPOTHESIS: THE QUEST FOR AN INTEGRATIVE ETIOLOGY OF DEPRESSION AND NEW THERAPEUTIC STRATEGIES -- Abstract -- Introduction -- The "Monoamine Hypothesis" of Depression -- Epigenetic Mechanisms in Depression -- Depression and Astrocytes: The Glia Cells Hypothesis -- Conclusion -- References -- Chapter 7 TIANEPTINE AND SERTRALINE: UNDERLYING NEUROCHEMICAL MECHANISMS OF ACTION.

1. Introduction -- 2. Clinical Changes in Patients with Anxious Depression Under Tianeptine and Sertraline Action. -- 3. Biochemical Changes in Anxious-Depressed Patients Under Antidepressant Therapy -- 4. The Role of Endogenous Intoxication in Pathogenetic Mechanism of Anxious Depression -- 5. Hormonal and Monoamine Interactions in Pathogenetic Mechanisms of anxious Depression -- 6. Neurochemical Mechanisms of Tianeptine and SSRIS Action: A Hypothesis. -- References -- Chapter 8 GENDER DIFFERENCES IN RESPONSE TO ANTIDEPRESSANTS -- Abstract -- Introduction -- Method -- Patients -- Inclusion Criteria -- Exclusion Criteria -- Statistical Analyses -- Results -- 1. The Baseline Characteristics of the Patients Treated with Fluvoxamine, Paroxetine, Sertraline, Milnacipran, and Maprotiline Are Shown in Table 1 -- 2. Total Remission Rate (Figure 1) -- 3. Gender Remission Rate (Figures 2 and 3) -- 4. Gender Remission Rate for Each Individual Antidepressant (Figure 4) -- Fluvoxamine -- Paroxetine -- Sertraline -- Milnacipran -- Maprotiline -- 5. Remission Rates of Males with First Episodes and Recurrent Episodes (Figure 5) -- 6. Remission Rates of Females with First Episodes and Recurrent Episodes (Figure 6) -- 7. Gender-Frequency of Remission Rates for Each Individual Antidepressant (Figure 7) -- Fluvoxamine -- Paroxetine -- Sertraline -- Milnacipran -- Maprotiline -- Discussion -- SSRI -- Sertraline -- Fluoxetine -- Citalopram -- Paroxetine and Fluvoxamine -- SNRI -- Milnacipran -- Venlafaxine and Duloxetine -- Selective Noradrenaline Reuptake Inhibitors -- Maprotiline and Reboxetine -- MAO inhibitors -- TCA -- Others -- Bupropion -- Conclusion -- References -- Expert Commentary ADULT NEUROGENESIS AND DEPRESSION: A NOVEL THEORY FOR DEPRESSION? -- References -- INDEX.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.